Recent Articles

Play the iShares Nasdaq Biotechnology Index (ETF)’s (IBB) Popularity for Free

ETFs should not move 11% in four days. The IBB just did that, so I will short it with no money out of pocket. Bet against the herd mentality. More 

Is the SPDR S&P Biotech (ETF) (XBI) Done Running?

Biotech stocks are booming, but resistance looms close. Time to take profits on the SPDR S&P Biotech (ETF) XBI calls, but also consider reloading. More 

This Market’s Biggest Problem? Energy.

As oil prices continue to languish, energy stocks keep weighing the S&P 500 down and disappointing investors. More 

Don’t Be Scared of Biogen Inc (BIIB) Stock

Pharma stocks like Biogen (BIIB) scare most investors. That means you can sell downside risk against unlikely scenarios in BIIB stock. More 

Trade of the Day: iShares Nasdaq Biotechnology Index (ETF) (IBB)

The past two trading days of risk-on in the IBB ETF has now led to a clear B2 reversal buy signal. Traders take note! More 

The Move in iShares Nasdaq Biotechnology Index (ETF) (IBB) ETF Is Coming — Get on Board

Chasing equity markets at these levels is risky. But I can instead use this play in the IBB ETF with a 15% buffer to create income. More 

iShares Nasdaq Biotechnology Index (ETF) (IBB): The Quick Guide to IBB

The $8 billion-plus iShares Nasdaq Biotechnology ETF (IBB) has a deep bench relative to other biotechnology funds. Is IBB right for you? More